Dasatinib Fails to Improve Outcomes in CBF-AML

Published Date: 24 Apr 2026

A phase 3 study investigates the outcomes associated with intensive chemotherapy with or without dasatinib in core-binding factor acute myeloid leukemia.

Read Full News

Latest News

Smartphone App Detects Eye Cancers From Photos

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Novel ADC Improves Survival in Metastatic TNBC

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Isatuximab Boosts MRD Negativity in Multiple Myeloma

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Fuzuloparib Add-On Improves Metastatic Prostate Cancer rPFS

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

Proton Therapy Fails to Beat IMRT in Prostate Cancer

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

Chiauranib Slows Platinum-Resistant Ovarian Cancer

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

Todays Updates

AI Saves Clinicians Time but Most Lack Training, Survey Finds

AI is saving clinicians time, but the majority of healthcare professionals say training in the technology is inadequate, ⁠inconsistent or unavailable, a global survey...

Hantavirus Outbreak Highlights the Importance of One Health

The recent hantavirus outbreak underscores how urbanization, deforestation, and rodent reservoirs can converge to shape zoonotic risk.

Alcohol Intake Tied to Increased Colorectal Cancer Risk

Dr Maurie Markman discusses a PLCO trial analysis highlighting the stark association between consistent heavy drinking and increased colorectal cancer risk.

AI Can Predict Breast Cancer Years Earlier. Too Good to Be True?

The short answer is yes. Dr F. Perry Wilson explains why he believes AI still has a role in radiology.

One Doctor’s Mission to Spread AI Literacy in Medicine

A medical oncologist seeks to use his computer science knowledge to make AI understandable to the medical community.

ASCO 2026: GI Oncology Shifts to Biomarker-Driven Care

Dr Emil Lou breaks down practice-changing GI oncology data from ASCO 2026, including transformative survival updates in pancreatic and upper GI cancers.

Interest in Alternative Menopause Treatments Surging

As menopause has become more visible online, experts see both benefits and risks, from greater patient engagement to the spread of misinformation.

Todays Updates

AI Saves Clinicians Time but Most Lack Training, Survey Finds

AI is saving clinicians time, but the majority of healthcare professionals say training in the technology is inadequate, ⁠inconsistent or unavailable, a global survey...

Hantavirus Outbreak Highlights the Importance of One Health

The recent hantavirus outbreak underscores how urbanization, deforestation, and rodent reservoirs can converge to shape zoonotic risk.

Alcohol Intake Tied to Increased Colorectal Cancer Risk

Dr Maurie Markman discusses a PLCO trial analysis highlighting the stark association between consistent heavy drinking and increased colorectal cancer risk.

AI Can Predict Breast Cancer Years Earlier. Too Good to Be True?

The short answer is yes. Dr F. Perry Wilson explains why he believes AI still has a role in radiology.

One Doctor’s Mission to Spread AI Literacy in Medicine

A medical oncologist seeks to use his computer science knowledge to make AI understandable to the medical community.

ASCO 2026: GI Oncology Shifts to Biomarker-Driven Care

Dr Emil Lou breaks down practice-changing GI oncology data from ASCO 2026, including transformative survival updates in pancreatic and upper GI cancers.

Interest in Alternative Menopause Treatments Surging

As menopause has become more visible online, experts see both benefits and risks, from greater patient engagement to the spread of misinformation.

Latest News

A smartphone app that analyzes images of the eye may enable early screening for cancers of the eye surface, flag lesions at high risk for specialist review, and expand access beyond clinics.

Izalontamab brengitecan extends overall survival among patients with metastatic TNBC, but it’s unclear how the investigational therapy might fit into an evolving treatment landscape.

Researchers compare two different treatment regimens in 446 transplant-ineligible patients with newly diagnosed multiple myeloma in a global phase 3 trial.

Researchers track progression-free survival after adding a PARP inhibitor to a standard regimen for metastatic castration-resistant prostate cancer.

For men with localized prostate cancer, proton therapy looks no better than IMRT when it comes to 3-year biochemical progression or GI toxicity.

The investigational drug extends progression-free survival in a phase 3 trial in patients with platinum-resistant or -refractory ovarian cancer.

News All Time

EMA Backs Breast Cancer SERD After FDA No Vote

The recommendation follows phase 3 data showing longer progression-free survival when patients switched to camizestrant plus a CDK4/6 inhibitor.

Datopotamab Deruxtecan Earns New Breast Cancer Indication

The antibody drug conjugate was approved by the FDA for certain patients with triple-negative breast cancer.

NP-Led Outreach Ups Cancer Screening in Rural Women Veterans

A nurse practitioner-led outreach program improves the rates of breast and cervical cancer screening among women veterans in rural areas, a retrospective study shows.

Less Mental Decline With Darolutamide vs Enzalutamide in PC

Over half of patients in a randomized trial switch from enzalutamide to darolutamide because of cognitive issues; no one switches in the opposite direction.

Revolutionary Cancer Tx Could Transform Autoimmune Disease

Researchers are testing CAR T-cell therapy as a way to reset the immune system in lupus, Graves’ disease and other conditions where the body’s defenses go rogue.

France Expands 2026 Vaccination Rules Amid Resurgence

Nearly 300 experts warn that rising vaccine misinformation is reversing gains — measles and meningococcal infections are resurging while France updates the 2026 schedule.

Antibiotic Stewardship: Five Tips to Reduce Resistance

Clinicians continue prescribing antibiotics unnecessarily despite growing evidence supporting shorter, targeted, and reassessed treatment strategies.

FDA Expands Use of T-DXd in Early HER2+ Breast Cancer

The agency OK’d trastuzumab deruxtecan for two indications in HER2-positive early-stage breast cancer, covering both the neoadjuvant and adjuvant settings.

Can Concurrent Boost Safely Shorten Breast Cancer Radiation?

Patients were randomly assigned 1:1 to receive either concurrent radiation dose escalation to the lumpectomy cavity during whole-breast irradiation or sequential boost after whole-breast irradiation.

Too Many Chest CTs for Incidental Lung Nodules?

Across 273 requests for chest CTs for incidental lung findings on neck imaging, only one indolent lung cancer was detected.

FDA Approves ctDNA-Guided Atezolizumab for Bladder Cancer

The approval of IV atezolizumab and atezolizumab with hyaluronidase-tqjs is the first for bladder cancer since a 2022 withdrawal of accelerated approval of atezolizumab for urothelial carcinoma.

All-Oral Treatment Combo for AML Earns FDA Nod

The combo, decitabine and cedazuridine tablets plus venetoclax, was approved for adults aged 75 and older and adults with comorbidities that preclude intensive induction chemotherapy.

Only 1 in 4 Eligible Adults Receive Lung Screening

Complicated eligibility rules, stigma surrounding smoking and lung cancer, and confusion about the screening process continue to keep many high-risk patients from getting screened.

Low PSA May Not Fully Predict Survival in Prostate Cancer

A recent post hoc analysis assesses whether PSA changes can predict survival outcomes in patients with metastatic or very high risk nonmetastatic prostate cancer.

FDA Warns of Secondary Blood Cancer Risk With Tazverik

The FDA says the increased risk of hematologic secondary primary malignancies with tazemetostat now outweighs the benefits of the drug; Ipsen pulls it from the market.

FDA Approves Next-Gen Agent for Mantle Cell Lymphoma

The BCL-2 inhibitor was granted accelerated approval based on findings from the phase 1/2 BGB-11417-201 study.

Recommended News For You

Survivors of childhood brain cancer are more likely to be held back in school

No Survival Gain With Preoperative CRT Plus Perioperative Chemo for Gastric Cancer

Rural colon cancer patients face higher risks, but minimally invasive surgery could narrow gap

a cutting-edge cancer diagnostic tool.

Breast cancer: Why it's difficult to treat and what new approaches are on the horizon

FDA Expands Approval of Osimertinib in Lung Cancer

Dasatinib Fails to Improve Outcomes in CBF-AML

Recommended Articles For You

Navigating the Complexities of Melanoma Staging: A Comprehensive Guide 

Radiation Oncology Advances: Guidelines, Trials, Digital Tools & Education 

Advancements in Survival Mechanisms and Prognostic Determinants in Acute Myeloid Leukemia 

Exploring Digital Cognitive Stimulation for Elderly Breast Cancer Patients 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

No PFS Benefit With Immune Checkpoint Inhibitor Rechallenge in Renal Cell Carcinoma

2.

Glioblastoma treatment breakthrough shows promise

3.

Omicron Infections Are Usually Cleared Up in Immunocompromised Patients.

4.

A novel blood test may enable the early identification of common, fatal cancers.

5.

WHO releases new R&D landscape analyses highlighting gaps and inequities in cancer research

1.

What You Need to Know about Hairy Cell Leukemia: A Comprehensive Guide 

2.

Chloride Test in HCC: Diagnostic Utility, Prognostic Role, and Emerging Insights

3.

Unlocking the Mystery of Glanzmann Thrombasthenia: A New Hope for Patients

4.

Exploring the Mysteries of MGUS: Uncovering the Causes and Treatments

5.

LncRNAs in Cancer: Shaping Tumor Progression & Paving New Paths for Treatment

1.

Asian Symposium on Advancement in Hematology and Oncology

2.

International Cancer Conference

3.

Asian Symposium on Advancement in Hematology and Oncology

4.

Asian Symposium on Advancement in Hematology and Oncology

5.

International Lung Cancer Congress®

1.

Redefining Treatment Pathways in Relapsed/Refractory Adult B-Cell ALL

2.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

3.

Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part III

4.

Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I

5.

Navigating the Complexities of Ph Negative ALL - Part VIII

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot